An Open-Label Pharmacokinetics and Safety Study of Talazoparib

NCT02997163

Last updated date
Study Location
Intertek USA, Inc.
San Diego, California, 92121, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.

2. Female or male of at least 18 years of age.

3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator

4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.

5. Expected life expectancy of ≥ 3 months.

6. Able to swallow the study drug (no contra indication to oral agents).

7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.

8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.

9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.

10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.

11. Adequate other organ function at screening and enrollment.

12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.

13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.

14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.

15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Treatment within 14 days or five half lives prior to enrollment with any type of
systemic anticancer-therapy or any investigational drug, whichever is longer.


2. Have not recovered (recovery is defined as CTCAE grade ≤ 1) from the acute toxicities
of previous anticancer standard or investigational therapy, except treatment-related
alopecia or laboratory abnormalities otherwise meeting eligibility requirements.


3. Major surgery within 28 days prior to enrollment.


4. Serious accompanying cardiac disorder.


5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing
or requiring treatment.


6. Symptomatic or impending spinal cord compression or cauda equina syndrome.


7. Has undergone a liver transplant, kidney transplant or nephrectomy.


8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious
adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly
ADP ribose polymerase (PARP) inhibitor.


9. Known myelodysplastic syndrome.


10. Seropositive for human immunodeficiency virus (HIV).


11. Any serious or unstable medical condition that interferes with ability to tolerate
treatment or assessments associated with the protocol.


12. Gastrointestinal disorder affecting absorption.


13. Known or suspected hypersensitivity to any of the talazoparib capsule components.


14. Any condition or reason that interferes with ability to participate in the study,
tolerate treatment or assessments associated with the protocol, causes undue risk, or
complicates the interpretation of safety data, in the opinion of the Investigator or
Medical Monitor.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Solid TumorsA Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
NCT02880371
  1. Los Angeles, California
  2. Aurora, Colorado
  3. Port Saint Lucie, Florida
  4. Lafayette, Indiana
  5. Boston, Massachusetts
  6. Detroit, Michigan
  7. Saint Paul, Minnesota
  8. Hershey, Pennsylvania
  9. Nashville, Tennessee
  10. San Antonio, Texas
  11. Salt Lake City, Utah
  12. Tacoma, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsA Study of Talazoparib in Patients With Advanced Solid Tumors
NCT03070548
  1. Budapest,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsFirst In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
NCT01469052
  1. San Francisco, California
  2. Houston, Texas
  3. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsThis Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
NCT00932126
  1. Santa Monica, California
  2. Aurora, Colorado
  3. East Melbourne, Victoria
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Official Title  ICMJE A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT
Brief Summary This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.
Detailed Description At the End of the Study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study after discussion with the Principal Investigator and obtaining Sponsor permission. Sponsor decision to allow the patient to continue dosing with talazoparib in an open-label extension study will be based on potential overall benefit-risk, patient acceptance and other relevant criteria.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumors
Intervention  ICMJE Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
  • MDV3800
  • BMN673
Study Arms  ICMJE
  • Experimental: Group A (control, normal renal function)
    Intervention: Drug: Talazoparib
  • Experimental: Group B (mild renal impairment)
    Intervention: Drug: Talazoparib
  • Experimental: Group C (moderate renal impairment)
    Intervention: Drug: Talazoparib
  • Experimental: Group D (severe renal impairment)
    Intervention: Drug: Talazoparib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 25, 2019)
34
Original Estimated Enrollment  ICMJE
 (submitted: December 15, 2016)
24
Actual Study Completion Date  ICMJE February 1, 2019
Actual Primary Completion Date January 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.
  2. Female or male of at least 18 years of age.
  3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator
  4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ? 2.
  5. Expected life expectancy of ? 3 months.
  6. Able to swallow the study drug (no contra indication to oral agents).
  7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.
  8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.
  9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.
  10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.
  11. Adequate other organ function at screening and enrollment.
  12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.
  13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.
  14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.
  15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

  1. Treatment within 14 days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer.
  2. Have not recovered (recovery is defined as CTCAE grade ? 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
  3. Major surgery within 28 days prior to enrollment.
  4. Serious accompanying cardiac disorder.
  5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing or requiring treatment.
  6. Symptomatic or impending spinal cord compression or cauda equina syndrome.
  7. Has undergone a liver transplant, kidney transplant or nephrectomy.
  8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.
  9. Known myelodysplastic syndrome.
  10. Seropositive for human immunodeficiency virus (HIV).
  11. Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.
  12. Gastrointestinal disorder affecting absorption.
  13. Known or suspected hypersensitivity to any of the talazoparib capsule components.
  14. Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02997163
Other Study ID Numbers  ICMJE MDV3800-01
C3441001 ( Other Identifier: Alias Study Number )
2016-002536-33 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Medivation, Inc.
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP